Amgen Inc.

Amgen Inc (AMGN)

  • BCG Recommendation

Balfour Capital Group Researched  Amgen Inc., on September 5th, 2023.

A biotechnology company headquartered in California, focused on innovative therapies in oncology, cardiovascular, and neuroscience, pioneering in biologics.

Post Recommendation Price Trend Chart

Analysts Research

With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
BCG Logo (white)

Company Snapshot

Balfour Capital Group's precise and thorough research crafted by our team of analysts.

Our Research

View

Thomson Reuters on AMGN

Thomson Reuters delivers global financial, legal, and business information to professionals.

Thomson Reuters Notes

View

Morgan Stanley on AMGN

Morgan Stanley researches industries, offers insights to clients.

Morgan Stanley Notes

View

Argus Analysts on AMGN

Argus Analysts Notes offers timely investment recommendations, insights.

Argus Analysts Notes

View

Argus Quantitive on AMGN

Argus Quantitative analyzes energy, commodities, and finance with data analytics.

Argus Quantitive Report

View
Amgen Inc.

2023 Q2 Earning Report

A Q2 report evaluates company financials for investors

Amgen Inc Report

View
Balfour Capital Group wants to clarify that our recommendation to Buy Amgen Inc (AMGN) is based on thorough research conducted by our dedicated teams. We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance. However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.

*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
error: Content is protected !!